NCCN Guidelines® insights acute lymphoblastic Leukemia, Version 1.2017 featured updates to the NCCN guidelines

Patrick A. Brown, Bijal Shah, Amir Fathi, Matthew Wieduwilt, Anjali Advani, Patricia Aoun, Stefan K. Barta, Michael W. Boyer, Teresa Bryan, Patrick W. Burke, Ryan Cassaday, Peter F. Coccia, Steven E. Coutre, Lloyd E. Damon, Daniel J. DeAngelo, Olga Frankfurt, John P. Greer, Hagop M. Kantarjian, Rebecca B. Klisovic, Gary KupferMark Litzow, Arthur Liu, Ryan Mattison, Jae Park, Jeffrey Rubnitz, Ayman Saad, Geoffrey L. Uy, Eunice S. Wang, Kristina M. Gregory, Ndiya Ogba

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. However, the management of relapsed or refractory (R/R) ALL remains challenging and prognosis is poor. The NCCN Guidelines for ALL provide recommendations on standard treatment approaches based on current evidence. These NCCN Guidelines Insights summarize treatment recommendations for R/R ALL and highlight important updates, and provide a summary of the panel's discussion and underlying data supporting the most recent recommendations for R/R ALL management.

Original languageEnglish (US)
Pages (from-to)1091-1102
Number of pages12
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number9
DOIs
StatePublished - Sep 1 2017

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this

Brown, P. A., Shah, B., Fathi, A., Wieduwilt, M., Advani, A., Aoun, P., Barta, S. K., Boyer, M. W., Bryan, T., Burke, P. W., Cassaday, R., Coccia, P. F., Coutre, S. E., Damon, L. E., DeAngelo, D. J., Frankfurt, O., Greer, J. P., Kantarjian, H. M., Klisovic, R. B., ... Ogba, N. (2017). NCCN Guidelines® insights acute lymphoblastic Leukemia, Version 1.2017 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 15(9), 1091-1102. https://doi.org/10.6004/jnccn.2017.0147